`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________
`
`SAMSUNG BIOEPIS CO., LTD.,
`Petitioner,
`
`
`v.
`
`REGENERON PHARMACEUTICALS, INC.,
`Patent Owner.
`
`Patent No. 11,253,572
`
`_______________
`
`Inter Partes Review No. IPR2023-00884
`____________________________________________________________
`
`PATENT OWNER’S OBJECTIONS TO EVIDENCE
`SUBMITTED WITH THE PETITION FOR INTER PARTES REVIEW
`
`
`
`
`
`
`
`
`IPR2023-00884
`
`
`
`
`
`Regeneron Pharmaceuticals, Inc. (“Regeneron” or “Patent Owner”) hereby
`
`objects to the following evidence that was submitted by Samsung Bioepis Co.,
`
`Ltd., (“Samsung” or “Petitioner”) with the Petition (“Pet.,” Paper 2) in the above-
`
`captioned proceeding.
`
`A. Exhibit 1002 (Expert Declaration of Dr. Edward Chaum in
`
`Support of Petition for Inter Partes Review of Patent No.
`
`11,253,572, dated April 27, 2023 (“Chaum Decl.”))
`
`Patent Owner objects to Exhibit 1002 under
`
`• FRE 402-403. The declaration is irrelevant, and its probative value is
`
`substantially outweighed by the danger of confusion of the issues and
`
`misleading the fact finder, including because Paragraphs 31 and 177 are not
`
`cited in the Petition.
`
`• FRE 801-804. The declaration constitutes hearsay to the extent that the
`
`declarant has not yet been made available for deposition.
`
`• FRE 106 and/or FRE 1006.
`
`o The declaration relies on excerpts of documents identified below. In
`
`fairness, the full document ought to be considered at the same time.
`
`o For example, at least Paragraphs 51, 54, 109, and 111-13, rely on
`
`incomplete evidence or improper summary and/or improperly cherry-
`
`1
`
`
`
`IPR2023-00884
`
`
`
`
`
`picking selective passages of a reference, while ignoring other
`
`passages in the same reference.
`
`• FRE 901.
`
`o The declaration relies on the unauthenticated evidence identified
`
`below.
`
`o Paragraph 180 relies on unauthenticated evidence. It is not clear
`
`where the image came from, how it was compiled, or what methods,
`
`materials, or metrics were used to arrive at the information in the
`
`image.
`
`B. Exhibit 1005 (Press Release, “Enrollment Completed in
`
`Regeneron and Bayer Healthcare Phase 3 Studies of VEGF Trap-
`
`Eye in Neovascular Age-Related Macular Degeneration (Wet
`
`AMD) (September 14, 2009),” available at:
`
`https://newsroom.regeneron.com/news-releases/newsrelease-
`
`details/enrollment-completed-regeneron-and-bayer-
`
`healthcarephase-3 (“2009 Press Release”))
`
`Patent Owner objects to Exhibit 1005 under
`
`• FRE 402 and 403. The exhibit is irrelevant, and its probative value is
`
`substantially outweighed by the danger of confusion of the issues and
`
`2
`
`
`
`IPR2023-00884
`
`
`
`
`
`misleading the fact finder, including to the extent Petitioner relies on this
`
`exhibit to show the results of a dosing regimen that it does not disclose.
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the exhibit. It
`
`is not clear where the exhibit came from or how it was compiled.
`
`C. Exhibit 1006 (Press Release, “Regeneron and Bayer Report
`
`Positive Results for VEGF Trap-Eye in Phase 3 Study in Central
`
`Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic
`
`Macular Edema (DME),” Exhibit 99.1 to Regeneron 8-K filed on
`
`December 20, 2010, available at:
`
`https://yahoo.brand.edgaronline.com/displayfilinginfo.aspx?Filing
`
`ID=7617341643623571&type=sect&TabIndex=2&companyid=503
`
`6&ppu=%252fdef% E2%80%A6 (“December 2010 Press
`
`Release”)
`
`Patent Owner objects to Exhibit 1006 under
`
`• FRE 402 and 403. The exhibit is irrelevant, and its probative value is
`
`substantially outweighed by the danger of confusion of the issues and
`
`misleading the fact finder, including because Petitioner relies on it as prior
`
`art to the challenged patent, but it is not prior art.
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the exhibit.
`
`3
`
`
`
`IPR2023-00884
`
`
`
`
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions, including because Petitioner relies
`
`on the reference itself for the date of publication online.
`
`D. Exhibit 1007 (Press Release, “Bayer and Regeneron Report
`
`Positive Top-Line Results of Two Phase 3 Studies with VEGF
`
`Trap-Eye in Wet Age-related Macular Degeneration,” Exhibit
`
`99.1 to Regeneron 8-K filed on November 22, 2010, available at:
`
`https://yahoo.brand.edgaronline.com/displayfilinginfo.aspx?Filing
`
`ID=7572010861126486&type=sect&TabIndex=2&companyid=503
`
`6&ppu=%252fdef%E2%80%A6 (“November 2010 Press
`
`Release”))
`
`Patent Owner objects to Exhibit 1007 under
`
`• FRE 402 and 403. The exhibit is irrelevant, and its probative value is
`
`substantially outweighed by the danger of confusion of the issues and
`
`misleading the fact finder, including because Petitioner relies on it as prior
`
`art to the challenged patent, but it is not prior art.
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the exhibit.
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions, including because Petitioner relies
`
`on the reference itself for the date of publication online.
`
`4
`
`
`
`IPR2023-00884
`
`
`
`
`
`E. Exhibit 1009 (Dixon JA, Oliver SC, Olson JL, Mandava N. VEGF
`
`Trap-Eye for the treatment of neovascular age-related macular
`
`degeneration. Expert Opin Investig Drugs. 2009;18(10):1573-
`
`1580. (“Dixon”))
`
`Patent Owner objects to Exhibit 1009 under
`
`• FRE 402 and 403. The exhibit is irrelevant, and its probative value is
`
`substantially outweighed by the danger of confusion of the issues and
`
`misleading the fact finder, including because Petitioner relies on this exhibit
`
`to show the results of a dosing regimen that it does not disclose.
`
`F. Exhibit 1010 (Major JC et al., “DA VINCI: DME and VEGF
`
`Trap-Eye: INvestigationof Clinical Impact: Phase 2 Study in
`
`Patients With Diabetic Macular Edema (DME), ARVO Annual
`
`Meeting Abstract (April 2010), Vol. 51, Issue 13, available at:
`
`https://iovs.arvojournals.org/article.aspx?articleid=2375028
`
`(“2010 ARVO Abstract”))
`
`Patent Owner objects to Exhibit 1010 under
`
`• FRE 402 and 403. The exhibit is irrelevant, and its probative value is
`
`substantially outweighed by the danger of confusion of the issues and
`
`misleading the fact finder, including because Petitioner relies on it as prior
`
`art to the challenged patent, but it is not prior art.
`
`5
`
`
`
`IPR2023-00884
`
`
`
`
`
`G. Exhibit 1016 (Hecht, “Opthalmic Preparations,” Remington: The
`
`Science and Practice of Pharmacy, Volume II, 19th edition,
`
`Chapter 89 (1995). (“Hecht”))
`
`Patent Owner objects to exhibit 1016 under
`
`• FRE 106 and/or FRE 1006. The Exhibit appears to be an excerpt. In
`
`fairness, the full document ought to be considered at the same time.
`
`H. Exhibit 1017 (WO 2006/047325 Al (“Shams”))
`
`Patent Owner objects to Exhibit 1017 under
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the exhibit. It
`
`is not clear where the exhibit came from or how it was compiled.
`
`I. Exhibit 1018 (Elman MJ, et al., Randomized trial evaluating
`
`ranibizumab plus prompt or deferred laser or triamcinolone plus
`
`prompt laser for diabetic macular edema. Ophthalmology. 2010
`
`Jun;117(6):1064-1077.e35. (“Elman 2010”))
`
`Patent Owner objects to Exhibit 1018 under
`
`• FRE 402 and 403. The exhibit is not relevant, and its probative value is
`
`substantially outweighed by the danger of confusion of the issues and
`
`misleading the fact finder.
`
`6
`
`
`
`IPR2023-00884
`
`
`
`
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the exhibit. It
`
`is not clear where the exhibit came from or how it was compiled.
`
`J. Exhibit 1019 (Elman MJ, et al., Randomized trial evaluating
`
`ranibizumab plus prompt or deferred laser or triamcinolone plus
`
`prompt laser for diabetic macular edema. Ophthalmology. 2010
`
`Jun;117(6):1064-1077.e35, published April 28 2010, available at
`
`https://www.aaojournal.org/article/S0161-6420(10)00243-
`
`5/fulltext (“Elman AAO Website))
`
`Patent Owner objects to Exhibit 1019 under
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the exhibit. It
`
`is not clear where the exhibit came from, how it was compiled, or what
`
`methods, materials, or metrics were used to arrive at the information in the
`
`document.
`
`K. Exhibit 1020 (Authenticating Affidavit and the July 13, 2010 Web
`
`Archive of the CATT Patient Eligibility Criteria, available at
`
`https://web.archive.org/web/20100713035617/http://www.med.upe
`
`7
`
`
`
`IPR2023-00884
`
`
`
`
`
`nn.edu/cpob/studies/documents/CATTEligibilityCriteria_000.pdf,
`
`attached as Exhibit B (“CATT Study”))
`
`Patent Owner objects to Exhibit 1020 under
`
`• FRE 402 and 403. The exhibit is not relevant, and its probative value is
`
`substantially outweighed by the danger of confusion of the issues and
`
`misleading the fact finder, including because Petitioner has not shown it was
`
`publicly accessible as of the priority date of the challenged claims of the
`
`’572 patent (January 13, 2011).
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the exhibit.
`
`L. Exhibit 1021 (Regillo CD, Brown DM, Abraham P, et al.
`
`Randomized, double-masked, sham-controlled trial of
`
`ranibizumab for neovascular age-related macular degeneration:
`
`PIER Study year 1. Am J Ophthalmol. 2008;145(2):239-248.
`
`(“PIER Study”))
`
`Patent Owner objects to Exhibit 1021 under
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the exhibit. It is
`
`not clear where the exhibit came from or how it was compiled.
`
`8
`
`
`
`IPR2023-00884
`
`
`
`
`
`M. Exhibit 1022 (Comparison of Age-related Macular Degeneration
`
`Treatments Trials: Lucentis-Avastin Trial (NCT00593450),
`
`available at: https://clinicaltrials.gov/ct2/show/NCT00593450
`
`(“NCT-450”))
`
`Patent Owner objects to Exhibit 1022 under
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the exhibit. It
`
`is not clear where the exhibit came from, how it was compiled, or what
`
`methods, materials, or metrics were used to arrive at the information in the
`
`document.
`
`N. Exhibit 1023 (Regillo CD, Brown DM, Abraham P, et al.
`
`Randomized, double-masked, sham-controlled trial of
`
`ranibizumab for neovascular age-related macular degeneration:
`
`PIER Study year 1. Am J Ophthalmol. 2008;145(2):239-248,
`
`published December 3, 2007, available at
`
`https://www.ajo.com/article/S0002-9394(07)00881-1/fulltext
`
`(“PIER AJO Website”))
`
`Patent Owner objects to Exhibit 1023 under
`
`9
`
`
`
`IPR2023-00884
`
`
`
`
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the exhibit. It
`
`is not clear where the exhibit came from, how it was compiled, or what
`
`methods, materials, or metrics were used to arrive at the information in the
`
`document.
`
`O. Exhibit 1024 (History of Changes for Study: A Study of rhuFab
`
`V2 (Ranibizumab) in Subjects With Subfoveal Choroidal
`
`Neovascularization Secondary to Age-Related Macular
`
`Degeneration (AMD) (NCT00090623), available at:
`
`https://clinicaltrials.gov/ct2/history/NCT00090623?V_1=View#Stu
`
`dyPageTop. (“NCT-623”))
`
`Patent Owner objects to Exhibit 1024 under
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the exhibit. It
`
`is not clear where the exhibit came from, how it was compiled, or what
`
`methods, materials, or metrics were used to arrive at the information in the
`
`document.
`
`P. Exhibit 1025 (ClinicalTrials.gov Background, available at:
`
`https://clinicaltrials.gov/ct2/about-site/background
`
`(“ClinicalTrials.gov Background”))
`
`Patent Owner objects to Exhibit 1025 under
`
`10
`
`
`
`IPR2023-00884
`
`
`
`
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the exhibit. It
`
`is not clear where the exhibit came from, how it was compiled, or what
`
`methods, materials, or metrics were used to arrive at the information in the
`
`document.
`
`Q. Exhibit 1026 (ClinicalTrials.gov About the Results Database,
`
`available at: https://clinicaltrials.gov/ct2/about-site/results
`
`(“ClinicalTrials.gov About the Results Database”))
`
`Patent Owner objects to Exhibit 1026 under
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the exhibit. It
`
`is not clear where the exhibit came from, how it was compiled, or what
`
`methods, materials, or metrics were used to arrive at the information in the
`
`document.
`
`R. Exhibit 1027 (Press Release, “Regeneron Reports Positive Phase 1
`
`Data for the VEGF TRAP in Age-Related Macular
`
`Degeneration,” Exhibit 99(a) to Regeneron 8-K filed on May 2,
`
`2006, available at:
`
`https://yahoo.brand.edgaronline.com/displayfilinginfo.aspx?Filing
`
`ID=4380124-5423-
`
`15279&type=sect&TabIndex=2&companyid=5036&ppu=%252fd
`
`ef%E2%80%A6 (“May 2006 Press Release”))
`
`11
`
`
`
`IPR2023-00884
`
`
`
`
`
`Patent Owner objects to Exhibit 1027 under
`
`• FRE 402 and 403. The exhibit is irrelevant, and its probative value is
`
`substantially outweighed by the danger of confusion of the issues and
`
`misleading the fact finder, including because Petitioner relies on this exhibit
`
`to show the results of a dosing regimen that it does not disclose.
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the exhibit. It
`
`is not clear where the exhibit came from, how it was compiled, or what
`
`methods, materials, or metrics were used to arrive at the information in the
`
`document.
`
`S. Exhibit 1030 (Do DV et al., “Results of a Phase I Study of
`
`Intravitreal VEGF Trap in Subjects With Diabetic Macular
`
`Edema: The CLEAR-IT DME Study,” ARVO Annual Meeting
`
`Abstract (May 2007), Vol. 48, Issue 3, available at:
`
`https://iovs.arvojournals.org/article.aspx?articleid=2384099
`
`(“2007 ARVO Abstract”))
`
`Patent Owner objects to Exhibit 1030 under
`
`• FRE 402 and 403. The exhibit is irrelevant, and its probative value is
`
`substantially outweighed by the danger of confusion of the issues and
`
`12
`
`
`
`IPR2023-00884
`
`
`
`
`
`misleading the fact finder, including because Petitioner relies on this exhibit
`
`to show the results of a dosing regimen that it does not disclose.
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the exhibit. It
`
`is not clear where the exhibit came from, how it was compiled, or what
`
`methods, materials, or metrics were used to arrive at the information in the
`
`document.
`
`• FRE 106 and/or FRE 1006. The Exhibit appears to be an excerpt. In
`
`fairness, the full document ought to be considered at the same time.
`
`T. Exhibit 1031 (Do DV et al., The DA VINCI Study: phase 2
`
`primary results of VEGF Trap-Eye in patients with diabetic
`
`macular edema. Ophthalmology. 2011 Sep;118(9):1819-26
`
`(published online on May 5, 2011). (“Do 2011”))
`
`Patent Owner objects to Exhibit 1031 under
`
`• FRE 402 and 403. The exhibit is not relevant, and its probative value is
`
`substantially outweighed by the danger of confusion of the issues and
`
`misleading the fact finder because it was not published before the priority
`
`date of the challenged claims of the ’572 patent (January 13, 2011).
`
`
`
`13
`
`
`
`IPR2023-00884
`
`
`
`
`
`U. Exhibit 1032 (Randolph and Jones, “Surfactant-Protein
`
`Interactions,” Rational Design of Stable Protein Formulations,
`
`edited by Carpenter and Manning, vol. 13, 2002 (“Randolph”))
`
`Patent Owner objects to Exhibit 1032 under
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`V. Exhibit 1034 (Lucentis ® Original Approved Labeling (2006),
`
`available at:
`
`https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/125156
`
`s0000_Lucentis_Prntlbl.pdf)
`
`Patent Owner objects to Exhibit 1034 under
`
`• FRE 402 and 403. The undated exhibit is not relevant, and its probative
`
`value is substantially outweighed by the danger of confusion of the issues
`
`and misleading the fact finder to the extent it is not shown to be published
`
`before the priority date of the challenged claims of the ’572 patent (January
`
`13, 2011).
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the document.
`
`It is not clear where the exhibit came from or how it was compiled.
`
`14
`
`
`
`IPR2023-00884
`
`
`
`
`
`W. Exhibit 1038 (Heier JS, et al., Intravitreal aflibercept (VEGF
`
`trap-eye) in wet agerelated macular degeneration. Ophthalmology
`
`2012;119(12):2537-2548. (“Heier 2012”))
`
`Patent Owner objects to Exhibit 1038 under
`
`• FRE 402 and 403. The exhibit is not relevant, and its probative value is
`
`substantially outweighed by the danger of confusion of the issues and
`
`misleading the fact finder because it was not published before the priority
`
`date of the challenged claims of the ’572 patent (January 13, 2011).
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`X. Exhibit 1039 (Heier JS, et al., CLEAR-IT 2 Investigators. The 1-
`
`year results of CLEAR-IT 2, a phase 2 study of vascular
`
`endothelial growth factor trapeye dosed as-needed after 12-week
`
`fixed dosing. Ophthalmology. 2011 Jun;118(6):1098-106. (“Heier
`
`2011”))
`
`Patent Owner objects to Exhibit 1039 under
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`Y. Exhibit 1040 (Pai A, El Shafei MM, Mohammed OA, Al Hashimi
`
`M., Current concepts in intravitreal drug therapy for diabetic
`
`15
`
`
`
`IPR2023-00884
`
`
`
`
`
`retinopathy. Saudi J Ophthalmol. 2010 Oct;24(4):143-9. (“Pai
`
`2010”))
`
`Patent Owner objects to Exhibit 1040 under
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`Z. Exhibit 1041 (U.S. Patent App. Pub. US 2007/0190058A1 (“Shams
`
`US App. Pub.”))
`
`Patent Owner objects to Exhibit 1041 under
`
`• FRE 402 and 403. The exhibit is irrelevant, and its probative value is
`
`substantially outweighed by the danger of confusion of the issues and
`
`misleading the fact finder, including because it is not cited in the Petition.
`
`AA.
`
`Exhibit 1043 (WO 2012/097019A1 (“Yancopoulos PCT
`
`Application”))
`
`Patent Owner objects to Exhibit 1043 under
`
`• FRE 402 and 403. The exhibit is irrelevant, and its probative value is
`
`substantially outweighed by the danger of confusion of the issues and
`
`misleading the fact finder, including because it is not cited in the Petition.
`
`BB.
`
`Exhibit 1044 (U.S. Dep’t Health & Human Servs., Nat’l
`
`Inst. Health, Nat’l Eye Inst.,“Diabetic Retinopathy: What You
`
`Should Know (Sept. 2015),” available at:
`
`16
`
`
`
`IPR2023-00884
`
`
`
`
`
`https://www.nei.nih.gov/sites/default/files/healthpdfs/Diabetic_Ret
`
`inopathy_What_You_Should_Know.pdf (“NIHDR”))
`
`Patent Owner objects to Exhibit 1044 under
`
`• FRE 402 and 403. The exhibit is irrelevant, and its probative value is
`
`substantially outweighed by the danger of confusion of the issues and
`
`misleading the fact finder, including because it is not cited in the Petition,
`
`and including because it was not published before the priority date of the
`
`challenged claims of the ’572 patent (January 13, 2011).
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the document.
`
`It is not clear where the exhibit came from or how it was compiled.
`
`CC.
`
`Exhibit 1045 (U.S. Dep’t Health & Human Servs., Nat’l
`
`Inst. Health, Nat’l Eye Inst.,“Age-Related Macular Degeneration:
`
`What You Should Know (Sept.2015),” available at
`
`https://www.nei.nih.gov/sites/default/files/healthpdfs/WYSK_AM
`
`D_English_Sept2015_PRINT.pdf (“NIH AMD”))
`
`Patent Owner objects to Exhibit 1045 under
`
`• FRE 402 and 403. The exhibit is not relevant, and its probative value is
`
`substantially outweighed by the danger of confusion of the issues and
`
`17
`
`
`
`IPR2023-00884
`
`
`
`
`
`misleading the fact finder, including because it was not published before the
`
`priority date of the challenged claims of the ’572 patent (January 13, 2011).
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the document.
`
`It is not clear where the exhibit came from or how it was compiled.
`
`DD.
`
`Exhibit 1046 (Halpern MT, Schmier JK, Covert D,
`
`Venkataraman K. Resource utilization and costs of age-related
`
`macular degeneration. Health Care Financ Rev. 2006;27(3):37-47.
`
`(“Halpern 2006”))
`
`Patent Owner objects to Exhibit 1046 under
`
`• FRE 402 and 403. The exhibit is irrelevant, and its probative value is
`
`substantially outweighed by the danger of confusion of the issues and
`
`misleading the fact finder, including because it is not cited in the Petition.
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`EE.
`
`Exhibit 1047 (Rudge JS, Holash J, Hylton D, et al. VEGF
`
`Trap complex formation measures production rates of VEGF,
`
`providing a biomarker for predicting efficacious angiogenic
`
`18
`
`
`
`IPR2023-00884
`
`
`
`
`
`blockade. Proc Natl Acad Sci U S A. 2007;104(47):18363-18370.
`
`(“Rudge 2007”))
`
`Patent Owner objects to Exhibit 1047 under
`
`• FRE 402 and 403. The exhibit is irrelevant, and its probative value is
`
`substantially outweighed by the danger of confusion of the issues and
`
`misleading the fact finder, including because it is not cited in the Petition.
`
`FF.
`
`Exhibit 1048 (Li E, Donati S, Lindsley KB, Krzystolik MG,
`
`Virgili G. Treatment regimens for administration of anti-vascular
`
`endothelial growth factor agents for neovascular age-related
`
`macular degeneration. Cochrane Database Syst Rev.
`
`2020;5(5):CD012208. (“Li 2020”))
`
`Patent Owner objects to Exhibit 1048 under
`
`• FRE 402 and 403. The exhibit is irrelevant, and its probative value is
`
`substantially outweighed by the danger of confusion of the issues and
`
`misleading the fact finder, including because it is not cited in the Petition,
`
`and including because it was not published before the priority date of the
`
`challenged claims of the ’572 patent (January 13, 2011).
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`19
`
`
`
`IPR2023-00884
`
`
`
`
`
`GG.
`
`Exhibit 1049 (Brown DM, Michels M, Kaiser PK, et al.
`
`Ranibizumab versus verteporfin photodynamic therapy for
`
`neovascular age-related macular degeneration: Two-year results
`
`of the ANCHOR study. Ophthalmology.2009;116(1):57-65.e5.
`
`(“Brown 2009”))
`
`Patent Owner objects to Exhibit 1049 under
`
`• FRE 403. The exhibit is irrelevant, and its probative value is substantially
`
`outweighed by the danger of confusion of the issues and misleading the fact
`
`finder, including because it is not cited in the Petition.
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`HH.
`
`Exhibit 1050 (Martin DF, Maguire MG, Fine SL, Ying GS,
`
`Jaffe GJ, Grunwald JE, et al, Comparison of Age-Related
`
`Macular Degeneration Treatments Trial (CATT) Research
`
`Group. Ranibizumab and bevacizumab for treatment of
`
`neovascular age-related macular degeneration: two-year results.
`
`Ophthalmology 2012; 119(7):1388-98 (“Martin”))
`
`Patent Owner objects to Exhibit 1050 under
`
`• FRE 403. The exhibit is irrelevant, and its probative value is substantially
`
`outweighed by the danger of confusion of the issues and misleading the fact
`
`20
`
`
`
`IPR2023-00884
`
`
`
`
`
`finder, including because it is not cited in the Petition, and including because
`
`its probative value is substantially outweighed by the danger of confusion of
`
`the issues and misleading the fact finder because it was not published before
`
`the priority date of the challenged claims of the ’572 patent (January 13,
`
`2011).
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`II. Exhibit 1051 (Chakravarthy U, Harding SP, Rogers CA, Downes
`
`SM, Lotery AJ, Wordsworth S, et al, Inhibition of VEGF in Age-
`
`related choroidal Neovascularization (IVAN) Study Investigators.
`
`Ranibizumab versus bevacizumab to treat neovascular age-
`
`related macular degeneration: one-year findings from the IVAN
`
`randomized trial. Ophthalmology 2012; 119(7):1399-411
`
`(“Chakravarthy 2012”)
`
`Patent Owner objects to Exhibit 1051 under
`
`• FRE 403. The exhibit is irrelevant, and its probative value is substantially
`
`outweighed by the danger of confusion of the issues and misleading the fact
`
`finder, including because it is not cited in the Petition, including because it
`
`was not published before the priority date of the challenged claims of the
`
`’572 patent (January 13, 2011).
`
`21
`
`
`
`IPR2023-00884
`
`
`
`
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`JJ. Exhibit 1052 (Rosenfeld PJ, Brown DM, Heier JS, Boyer DS,
`
`Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-
`
`related macular degeneration. New England Journal of Medicine
`
`2006; 355(14):1419-31 (“Rosenfeld 2006”))
`
`Patent Owner objects to Exhibit 1052 under
`
`• FRE 403. The exhibit is irrelevant, and its probative value is substantially
`
`outweighed by the danger of confusion of the issues and misleading the fact
`
`finder, including because it is not cited in the Petition.
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`KK.
`
`Exhibit 1053 (Heimann, H. (2007). Chapter 5 Intravitreal
`
`Injections: Techniques and Sequelae. In: Holz, F.G., Spaide, R.F.
`
`(eds) Medical Retina. Essentials in Ophthalmology. Springer,
`
`Berlin, Heidelberg. (“Heimann 2007”))
`
`Patent Owner objects to Exhibit 1053 under
`
`• FRE 403. The exhibit is irrelevant, and its probative value is substantially
`
`outweighed by the danger of confusion of the issues and misleading the fact
`
`finder, including because it is not cited in the Petition.
`
`22
`
`
`
`IPR2023-00884
`
`
`
`
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`LL.
`
`Exhibit 1054 (Jager RD, Aiello LP, Patel SC, Cunningham
`
`ET Jr. Risks of intravitreous injection: a comprehensive review.
`
`Retina. 2004;24(5):676-698. (“Jager 2004”))
`
`Patent Owner objects to Exhibit 1054 under
`
`• FRE 403. The exhibit is irrelevant, and its probative value is substantially
`
`outweighed by the danger of confusion of the issues and misleading the fact
`
`finder, including because it is not cited in the Petition.
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`MM.
`
`Exhibit 1056 (Pilot Study of Intravitreal Injection of
`
`Ranibizumab for Macular Telangiectasia With
`
`Neovascularization (NCT00685854) (May 24, 2008), available at:
`
`https://clinicaltrials.gov/ct2/history/NCT00685854?V_1=View#Stu
`
`dyPageTop (“MACTEL Study”))
`
`Patent Owner objects to Exhibit 1056 under
`
`• FRE 403. The exhibit is irrelevant, and its probative value is substantially
`
`outweighed by the danger of confusion of the issues and misleading the fact
`
`finder, including because it is not cited in the Petition.
`
`23
`
`
`
`IPR2023-00884
`
`
`
`
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the exhibit. It
`
`is not clear where the exhibit came from or how it was compiled.
`
`NN.
`
`Exhibit 1057 (Authenticating Affidavit and the November 7,
`
`2008 Web Archive of Ranibizumab Injections to Treat Macular
`
`Telangiectasia Without New Blood Vessel Growth
`
`(NCT00685854), available at
`
`https://web.archive.org/web/20081107014243/https://clinicaltrials.
`
`gov/ct2/show/NCT00685854, attached as Exhibit A (“MACTEL
`
`Study Wayback Machine”))
`
`Patent Owner objects to Exhibit 1057 under
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the exhibit.
`
`OO.
`
`Exhibit 1058 (Using the Wayback Machine, available at:
`
`https://help.archive.org/help/using-the-wayback-machine/)
`
`Patent Owner objects to Exhibit 1058 under
`
`• FRE 403. The exhibit is irrelevant, and its probative value is substantially
`
`outweighed by the danger of confusion of the issues and misleading the fact
`
`finder, including because it is not cited in the Petition.
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the exhibit. It
`
`is not clear where the exhibit came from or how it was compiled.
`
`24
`
`
`
`IPR2023-00884
`
`
`
`
`
`PP.
`
`Exhibit 1059 (Eylea Label 2011 available at:
`
`https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/12538
`
`7lbl.pdf)
`
`Patent Owner objects to Exhibit 1059 under
`
`• FRE 403. The exhibit is irrelevant, and its probative value is substantially
`
`outweighed by the danger of confusion of the issues and misleading the fact
`
`finder, including because it is not cited in the Petition.
`
`• FRE 901. Petitioner has not demonstrated the authenticity of the document.
`
`It is not clear where the exhibit came from or how it was compiled.
`
`QQ.
`
`Exhibit 1060 (Glenn J. Jaffe, Paul Ashton, P. Andrew
`
`Pearson, Intraocular Drug Delivery (2006) (“Jaffe”))
`
`Patent Owner objects to Exhibit 1060 under
`
`• FRE 402 and 403. The exhibit is not relevant, and its probative value is
`
`substantially outweighed by the danger of confusion of the issues and
`
`misleading the fact finder, including because it is not cited in the Petition.
`
`• FRE 802. The exhibit is offered for the truth of its content without
`
`satisfying any of the hearsay exceptions.
`
`RR.
`
`Exhibit 1061 (Steps for a Safe Intravitreal Injection
`
`Technique (2009), available at:
`
`25
`
`
`
`IPR2023-00884
`
`
`
`
`
`https://www.retinalphysician.com/issues/2009/July aug/steps-for-
`
`asafe-intravitreal-injection-technique)
`
`Patent Owner objects to Exhibit 1061 under
`
`• FRE 403. The exhibit is irrelevant, and its probative value is substantially
`
`outweighed by the danger of confusion of the issues and misleading the fact
`
`finder, including because it is not cited in the Petition.
`
`
`To the extent the exhibits are admitted, their scope should be restricted to the
`
`purpose for which they were originally submitted. FRE 105. Should Samsung rely
`
`on an exhibit for a different purpose than the one for which it has been offered,
`
`Regeneron reserves the right to make additional objections.
`
`
`
`In accordance with 37 C.F.R. § 42.64(b)(1), these objections are being
`
`timely filed and served within ten (10) business days of the institution of the trial
`
`by the Patent and Trial Appeal Board (“Board”), which is reflected in the Board’s
`
`Institution Decision dated November 17, 2023 (Paper 13).
`
`26
`
`
`
`IPR2023-00884
`
`
`
`
`
`Dated: December 4, 2023
`
`
`
`
`
`Respectfully submitted,
`
`
`By /Adam R. Brausa/
`Adam R. Brausa, Reg. No. 60,287
`MORRISION & FOERSTER LLP
`425 Market Street
`San Francisco, California 94105
`Tel: (415) 268-6053
`ABrausa@mofo.com
`
`Attorney for Patent Owner
`
`27
`
`
`
`IPR2023-00884
`
`
`
`
`
`Certificate of Service (37 C.F.R. § 42.6(e)(4))
`
`
`
`I hereby certify that the attached PATENT OWNER’S OBJECTIONS TO
`
`EVIDENCE SUBMITTED WITH THE PETITION FOR INTER PARTES
`
`REVIEW was served as of the below date on the Petitioner via e-mail (by
`
`agreement) to the following counsel of record.
`
`Raymond N. Nimrod (Reg. No. 31,987)
`Matthew A. Traupman (Reg. No. 50,832)
`Landon Andrew Smith (Reg. No. 79,248)
`QUINN EMANUEL URQUHART
`& SULLIVAN, LLP
`51 Madison Ave., 22nd Floor
`New York, NY 10010
`General Tel: (212) 849-7000
`Email: raynimrod@quinnemanuel.com
`Email: matthewtraupman@quinnemanuel.com
`Email: landonsmith@quinnemanuel.com
`Email: qe-samsungbioepis@quinnemanuel.com
`
`
`Dated: December 4, 2023
`
`/Adam R. Brausa/
`Adam R. Brausa, Reg. No. 60,287
`
`
`
`28
`
`